ES2530578T3 - Crystals and cross-linked crystals of Protein A and methods of use thereof - Google Patents

Crystals and cross-linked crystals of Protein A and methods of use thereof Download PDF

Info

Publication number
ES2530578T3
ES2530578T3 ES10817707T ES10817707T ES2530578T3 ES 2530578 T3 ES2530578 T3 ES 2530578T3 ES 10817707 T ES10817707 T ES 10817707T ES 10817707 T ES10817707 T ES 10817707T ES 2530578 T3 ES2530578 T3 ES 2530578T3
Authority
ES
Spain
Prior art keywords
crystals
protein
cross
methods
linked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10817707T
Other languages
Spanish (es)
Inventor
Bhami Shenoy
Reena Patel
Sibyl Baladi
Margaret Mcgrath
Nazar Khalaf
Chanchai Randhawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2530578T3 publication Critical patent/ES2530578T3/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Abstract

Una composición que comprende forma cristalina reticulada de Proteína A.A composition comprising cross-linked crystalline form of Protein A.

ES10817707T 2009-09-15 2010-09-13 Crystals and cross-linked crystals of Protein A and methods of use thereof Active ES2530578T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24253709P 2009-09-15 2009-09-15
PCT/US2010/048664 WO2011034822A1 (en) 2009-09-15 2010-09-13 Protein a crystals and cross-linked crystals and methods of use thereof

Publications (1)

Publication Number Publication Date
ES2530578T3 true ES2530578T3 (en) 2015-03-03

Family

ID=43758972

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10817707T Active ES2530578T3 (en) 2009-09-15 2010-09-13 Crystals and cross-linked crystals of Protein A and methods of use thereof

Country Status (12)

Country Link
US (2) US8921531B2 (en)
EP (1) EP2478005B1 (en)
JP (1) JP5700581B2 (en)
KR (1) KR101530417B1 (en)
CN (1) CN102753570B (en)
BR (1) BR112012005869A2 (en)
CA (1) CA2774212C (en)
DK (1) DK2478005T3 (en)
EA (1) EA033141B1 (en)
ES (1) ES2530578T3 (en)
HK (1) HK1173457A1 (en)
WO (1) WO2011034822A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5700581B2 (en) 2009-09-15 2015-04-15 アジノモト アルシア， インコーポレイテッド Protein A crystals and cross-linked crystals and methods of use thereof
JP5963538B2 (en) * 2012-02-24 2016-08-03 三井造船株式会社 Genetic recombination method for Morella bacteria
JP6147340B2 (en) * 2013-05-29 2017-06-14 Jsr株式会社 Cleaning composition, protein purification method, and protein
US9546208B2 (en) 2014-01-03 2017-01-17 Bio-Rad Laboratories, Inc. Removal of impurities from protein A eluates
WO2016031932A1 (en) * 2014-08-27 2016-03-03 田辺三菱製薬株式会社 METHOD FOR PRODUCING PROTEIN HAVING Fc REGION BY ALKALI WASHING
AR103726A1 (en) * 2015-02-27 2017-05-31 Merck Sharp & Dohme HUMAN ANTI-PD-1 MONOCLONAL ANTIBODY CRYSTALS
CA3046561A1 (en) * 2016-12-12 2018-06-21 Hurrah S.A R.L. Compositions and methods for increasing the immunoglobulin binding capacities of immunoglobulin-binding polypeptides and oligopeptides
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
CA3060581A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
CN112816700A (en) * 2020-12-28 2021-05-18 杭州新脉生物科技有限公司 Colloidal gold test strip for detecting HIV antibody in urine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS508549A (en) 1973-05-21 1975-01-29
UA27035C2 (en) * 1990-08-03 2000-02-28 Вертекс Фармас'Ютікалс Інкорпорейтід crystal of protein cross-linked with multi-functional linking agent (variants), appliance that includes crystal of protein and method to obtain aspartame
US5618710A (en) 1990-08-03 1997-04-08 Vertex Pharmaceuticals, Inc. Crosslinked enzyme crystals
AU628264B2 (en) 1990-08-14 1992-09-10 Oracle International Corporation Methods and apparatus for providing a client interface to an object-oriented invocation of an application
AU2429397A (en) 1996-03-29 1997-10-22 David S. Terman Polymerized staphylococcal protein a for treatment of diseases
US6140475A (en) 1997-04-11 2000-10-31 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
CN101120017A (en) 2004-08-30 2008-02-06 英国龙沙生物医药股份有限公司 Affinity-plus ion exchange-chromatography for purifying antibodies
JP5700581B2 (en) 2009-09-15 2015-04-15 アジノモト アルシア， インコーポレイテッド Protein A crystals and cross-linked crystals and methods of use thereof

Also Published As

Publication number Publication date
CN102753570A (en) 2012-10-24
EA201270425A1 (en) 2013-02-28
DK2478005T3 (en) 2015-02-16
CA2774212C (en) 2018-01-30
US8921531B2 (en) 2014-12-30
JP2013504621A (en) 2013-02-07
CA2774212A1 (en) 2011-03-24
US20150239962A1 (en) 2015-08-27
KR101530417B1 (en) 2015-06-19
HK1173457A1 (en) 2013-05-16
EP2478005A1 (en) 2012-07-25
JP5700581B2 (en) 2015-04-15
BR112012005869A2 (en) 2017-01-31
US9273123B2 (en) 2016-03-01
EP2478005B1 (en) 2014-11-12
KR20140002459A (en) 2014-01-08
EA033141B1 (en) 2019-09-30
WO2011034822A1 (en) 2011-03-24
US20130053548A1 (en) 2013-02-28
CN102753570B (en) 2016-01-20
EP2478005A4 (en) 2013-07-24

Similar Documents

Publication Publication Date Title
ES2530578T3 (en) Crystals and cross-linked crystals of Protein A and methods of use thereof
CR20140180A (en) HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS
BRPI0818003A2 (en) csf-1r inhibitors, compositions and methods of use
BRPI1012533A2 (en) pyradazinone compound and use thereof
BRPI0916769A2 (en) deuterated benzylbenzene derivatives and methods of use
DK2419429T3 (en) IMIDAZOPYRAZINES AS INHIBITORS OF PROTEIN CHINAS
BRPI0822104A2 (en) ANTIMICROBIAN COMPOSITIONS AND METHODS FOR THE USE OF THE SAME
DK2178888T3 (en) proteasome inhibitors
BRPI1007494A2 (en) compound and use thereof
BR112012002349A2 (en) compound and use thereof
BRPI1011384A2 (en) proproteins and their methods of use
DK2504332T4 (en) AMORPHIC FORM AND CRYSTALLINIC FORM OF GENZ 112638 HEMITARTRATE AS INHIBITOR OF GLUCOSYLCERAMID SYNTHASIS
BRPI0915231A2 (en) kinase inhibitor compounds and methods of use
BRPI0915928A2 (en) compositions and methods of use for therapeutic antibodies
BRPI0821668A2 (en) Use
BRPI0813627A2 (en) ANTIMICROBIAN PEPTIDIA, COMPOSITIONS AND METHODS OF USE
DK2211901T3 (en) VACCINATION WITH MULTIPLE CLADER OF H5-INFLUENZA-A-VIRUS
BRPI0911332A2 (en) compositions and use of epas1 inhibitors
UY33754A (en) MONOBACTAMAS
CR20110576A (en) ANTI-EGFL7 HUMANIZED ANTIBODIES AND METHODS OF USE OF THE SAME
BR112012001797A2 (en) bicyclic compound and its use for medical purposes
BRPI1005670A2 (en) adjuvant compositions and methods of use
BRPI0812159A2 (en) csf-1r inhibitors, compositions and methods of use
BRPI0922344A2 (en) tfpi inhibitors and methods of use
BRPI0813263A2 (en) REPLACED OXAZOLIDINONES AND THEIR USE